Literature DB >> 9552992

Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be.

M M Breteler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9552992      PMCID： PMC1112980          DOI： 10.1136/bmj.316.7139.1182

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  6 in total

1.  Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.

Authors:  Y Ben-Shlomo; A Churchyard; J Head; B Hurwitz; P Overstall; J Ockelford; A J Lees
Journal:  BMJ       Date:  1998-04-18

Review 2.  Selegiline and mortality in Parkinson's disease.

Authors:  C W Olanow; S Fahn; J W Langston; J Godbold
Journal:  Ann Neurol       Date:  1996-12       Impact factor: 10.422

3.  Unexpected findings of study of selegiline have not been treated with caution its authors advised.

Authors:  M T Silva; A H Schapira; P Jenner
Journal:  BMJ       Date:  1997-08-09

4.  Effect of deprenyl on the progression of disability in early Parkinson's disease.

Authors: 
Journal:  N Engl J Med       Date:  1989-11-16       Impact factor: 91.245

5.  Prevalence of Parkinson's disease in the elderly: the Rotterdam Study.

Authors:  M C de Rijk; M M Breteler; G A Graveland; A Ott; D E Grobbee; F G van der Meché; A Hofman
Journal:  Neurology       Date:  1995-12       Impact factor: 9.910

6.  Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.

Authors:  A J Lees
Journal:  BMJ       Date:  1995-12-16
  6 in total
  2 in total

Review 1.  Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.

Authors:  E H Heinonen; V Myllylä
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

Review 2.  Monoamine oxidase B inhibitors for early Parkinson's disease.

Authors:  A D Macleod; C E Counsell; N Ives; R Stowe
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.